Prostatic Neoplasm Clinical Trials in Cleveland, Ohio
6 recruitingCleveland, Ohio
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Prostatic Neoplasms
Janssen Research & Development, LLC40 enrolled5 locationsNCT07319871
Recruiting
Phase 1
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Prostatic Neoplasms
Janssen Research & Development, LLC140 enrolled6 locationsNCT07082920
Recruiting
Phase 1Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Not Applicable
Investigation of Impact of AI on Prostate Cancer Workflow
Prostate CancerProstatic NeoplasmCancer of the Prostate+1 more
Case Comprehensive Cancer Center150 enrolled1 locationNCT07084779
Recruiting
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Bayer1,400 enrolled1 locationNCT07406282